ÂÜÀòÂÒÂ×

Chris is Managing Director, Biotechnology Investments (Public & Private) at Alpha Wave Global. He currently serves as a board director for Apnimed, Dunad Therapeutics and Cour Pharmaceuticals. Previously, Chris worked in prominent buy-side portfolio management roles, including at Citadel Investment Group, Millennium Partners and J. Goldman, and prior to that in equity research, including with JP Morgan. Most recently, Chris served as founder and CEO of a biotechnology company focused on the development of oligonucleotides for CNS disorders.

Chris graduated from John Hopkins University with a M.S. in Biotechnology and from the University of Illinois with a B.S. in Finance.